SCOPUS 정보 검색 플랫폼

Volumn 85, Issue 8, 2001, Pages 1124-1129

Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer

(10) Gelderblom, H a,d Sparreboom, A a Jonge, M J A a Loos, W J a Wilms, E a Mantel, M A a Hennis, B b Camlett, I c Verweij, J a Burg, M E L a

a ERASMUS MEDICAL CENTER (Netherlands)

b SmithKline Beecham Pharmaceuticals (Netherlands)

c GLAXOSMITHKLINE (United Kingdom)

d LEIDEN UNIVERSITY MEDICAL CENTER (Netherlands)

Author keywords

Cisplatin; Cremophor EL; Oral topotecan; Ovarian cancer

Indexed keywords

CISPLATIN; CREMOPHOR; PACLITAXEL; TOPOTECAN;

ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER RECURRENCE; CLINICAL TRIAL; DOSE RESPONSE; DRUG FORMULATION; HUMAN; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLYCEROL; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; TOPOTECAN;

EID: 0035914260 PISSN: 00070920 EISSN: None Source Type: Journal
DOI: 10.1054/bjoc.2001.2014 Document Type: Article

Times cited : (11)

References (22)

1
- 0033975343
- Differential alteration of cisplatin cytotoxicity and myelotoxicity by the vehicle Cremophor EL
- (2000) Naunyn-Schmiedeberg Arch Pharmacol , vol.361 , pp. 339-334
- Badary, O.A.¹ Abdel-Naim, A.B.² Khalifa, A.E.³ Hamada, F.M.A.⁴

2
- 0028153260
- Computerised quantitation of synergism and antagonism of Taxol, Topotecan and Cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design
- (1994) J Natl Cancer Inst , vol.86 , pp. 1517-1524
- Chou, T.C.¹ Motze, R.J.² Tong, Y.³ Bosl, G.J.⁴

3
- 0030762571
- Case report of anaphylaxis from cisplatin/paclitaxel and a review of their hypersensitivity reaction profiles
- (1997) Am J Clin Oncol (CCT) , vol.20 , pp. 373-375
- Ciesielski-Carlucci, C.¹ Leong, P.² Jacobs, C.³

4
- 85069079158
- Topotecan, an active drug in the second line treatment of epithelian ovarian cancer: Results of a large European Phase II study
- (1994) J Clin Oncol , vol.12 , pp. 1748-1753
- Creemers, G.J.¹ Bolls, G.² Gore, M.³ Scarfone, G.⁴ Lacave, A.J.⁵ Guastalla, J.P.⁶ Despax, R.⁷ Favalli, G.⁸ Kleinberg, R.⁹ Van Belle, S.¹⁰ Hudson, I.¹¹ Verweij, J.¹² Ten Bokkel Huinink, W.W.¹³

5
- 17144433130
- Phase I and pharmacological study of oral topotecan and intravenous cisplatin: Sequence-dependent haematologic side effects
- (2000) J Clin Oncol , vol.18 , pp. 2104-2115
- De Jonge, M.J.A.¹ Loos, W.J.² Gelderblom, H.J.³ Planting, A.S.T.⁴ Van der Burg, M.E.L.⁵ Sparreboom, A.⁶ Brouwer, E.⁷ Van Beurden, V.⁸ Mantel, M.⁹ Doyle, E.¹⁰ Hearn, S.¹¹ Ross, G.¹² Verweij, J.¹³

6
- 9844220294
- Differential modulation of cisplatin, accumulation in leukocytes and tumour cell lines by the paclitaxel vehicle Cremophor EL
- (1997) Ann Oncol , vol.8 , pp. 1145-1150
- De Vos, A.I.¹ Nooter, K.² Verweij, J.³ Loos, W.J.⁴ Brouwer, E.⁵ De Bruijn, E.⁶ Ruijgrok, E.J.⁷ Van der Burg, M.E.L.⁸ Stoter, G.⁹ Sparreboom, A.¹⁰

7
- 85069083538
- Submitted
- (2000) Modulation of cisplatin pharmacodynamics by Cremophor EL: Experimental and clinical studies
- Gelderblom, H.¹ Loos, W.J.² Verweij, J.³ Brouwer, E.⁴ Van der Burg, M.E.L.⁵ Sparreboom, A.⁶

8
- 0033789366
- Phase I and pharmacological study of increased dose oral topotecan in combination with intravenous cisplatin
- (2000) Ann Oncol , vol.11 , pp. 1205-1207
- Gelderblom, H.¹ Loos, W.J.² De Jonge, M.J.A.³ Sparreboom, A.⁴ Planting, A.S.T.⁵ Van der Burg, M.E.L.⁶ Brouwer, E.⁷ Verheij, C.⁸ Ouwens, L.⁹ Hearn, S.¹⁰ Verweij, J.¹¹

9
- 0032101820
- Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours
- (1998) Eur J of Cancer , vol.34 , pp. 1030-1035
- Gerrits, C.J.H.¹ Burris, H.² Schellens, J.H.M.³ Planting, A.S.T.⁴ Van der Burg, M.E.L.⁵ Rodriguez, G.I.⁶ Van Beurden, V.⁷ Loos, W.J.⁸ Hudson, I.⁹ Fields, S.¹⁰ Verweij, J.¹¹ Von Hoff, D.D.¹²

10
- 0000292001
- A multicentre randomized phase III study of topotecan administered intravenously or orally for advanced epithelial ovarian carcinoma
- abstr
- (1998) Proc ASCO , vol.17 , pp. 1346
- Gore, M.¹ Rustin, G.² Calvert, H.³ Bezwoda, W.⁴ Carmichael, J.⁵ Oza, A.⁶ Kaye, S.⁷ Ten Bokkel Huinink, W.⁸ Malfetano, J.⁹ Falkson, G.¹⁰ Clarke-Pearson, D.¹¹ Ross, G.A.¹² Dane, G.C.¹³ Fields, S.Z.¹⁴

11
- 0028357995
- Phase I trial of low continuous topotecan infusion in patients with cancer: An active and well tolerated regimen
- (1994) J Clin Oncol , vol.12 , pp. 553-559
- Hochster, H.¹ Liebes, L.² Speyer, J.³ Sorich, J.⁴ Taubes, B.⁵ Oratz, R.⁶ Wernz, J.⁷ Chachoua, A.⁸ Blum, R.H.⁹ Zeleniuch-Jacquotte, A.¹⁰

12
- 0031017851
- Patient preferences for oral versus intravenous palliative chemotherapy
- (1997) J Clin Oncol , vol.15 , pp. 110-115
- Liu, G.¹ Franssen, E.² Fitch, M.I.³ Warner, E.⁴

13
- 0030070073
- Docetaxel and paclitaxel inhibit DNA adduct formation and intracellular accumulation of cisplatin in human leukocytes
- (1996) Cancer Chemother Pharmacol , vol.36 , pp. 382-382
- Ma, J.¹ Verweij, J.² Planting, A.S.T.³ Kolker, H.J.⁴ Loos, W.J.⁵ De Boer-Dennert, M.⁶ Van der Burg, M.E.L.⁷ Stoter, G.⁸ Schellens, J.H.M.⁹

14
- 0031745255
- Chemotherapy of advanced ovarian cancer
- (1998) Semin Oncol , vol.25 , pp. 340-348
- McGuire, W.P.¹ Ozols, R.F.²

15
- 0027999967
- Phase I study of topotecan and cisplatin in patients with advanced solid tumours: A cancer and leukemia group B study
- (1994) J Clin Oncol , vol.12 , pp. 2743-2750
- Miller, A.A.¹ Hargis, B.J.² Lilenbaum, R.C.³ Fields, S.Z.⁴ Rosner, G.L.⁵ Schilsky, R.L.⁶

16
- 0031014450
- Cancer statistics, 1997
- (1997) CA Cancer J Clin , vol.47 , pp. 5-27
- Parker, S.L.¹ Tong, T.² Bolden, S.³ Wingo, P.A.⁴

17
- 0031905299
- In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems
- (1998) Cancer Chemother Pharmacol , vol.41 , pp. 385-390
- Romanelli, S.¹ Perego, P.² Pratesi, G.³ Carenini, N.⁴ Tortoreto, M.⁵ Zunino, F.⁶

18
- 10544249871
- Sequences of topotecan and cisplatin: Phase I, pharmacologic, and in vitro studies to examine sequence dependence
- (1996) J Clin Oncol , vol.14 , pp. 3074-3084
- Rowinsky, E.K.¹ Kaufmann, S.H.² Baker, S.D.³ Grochow, L.B.⁴ Chen, T.-L.⁵ Peereboom, D.⁶ Bowling, M.K.⁷ Sartorius, S.E.⁸ Ettinger, D.S.⁹ Forastiere, A.A.¹⁰ Donehower, R.C.¹¹

19
- 0031239998
- Topotecan in Platinum-and Paclitaxel-resistant ovarian cancer
- (1997) Gyn Oncol , vol.66 , pp. 480-486
- Swisher, E.M.¹ Mutch, D.G.² Rader, J.S.³ Elbendary, A.⁴ Herzog, T.J.⁵

20
- 0030900145
- Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
- (1997) J Clin Oncol , vol.15 , pp. 2183-2193
- Ten Bokkel Huinink, W.¹ Gore, M.² Carmichael, J.³ Gordon, A.⁴ Malfetano, J.⁵ Hudson, I.⁶ Broom, C.⁷ Scarabelli, C.⁸ Davidson, N.⁹ Spanczynski, M.¹⁰ Bolis, G.¹¹ Malmstrom, H.¹² Coleman, R.¹³ Fields, S.C.¹⁴ Heron, J.F.¹⁵

21
- 0000360616
- Weekly high dose cisplatin and oral vepesid: A highly active regimen for ovarian cancer failing on or relapsing after conventional platinum containing combination chemotherapy
- abstract
- (1996) Proc ASCO , vol.15 , pp. 722
- Van der Burg, M.E.L.¹ Logmans, A.² De Wit, R.³ Van Lent, M.⁴ Kruit, W.J.H.⁵ Stoter, G.⁶ Verweij, J.⁷

22
- 0002360126
- Phase I study of weekly cisplatin and weekly or 4-weekly taxol: A highly active regimen in advanced epithelian cancer
- abstr
- (1998) Proc ASCO , vol.17 , pp. 1370
- Van der Burg, M.E.L.¹ De Wit, R.² Stoter, G.³ Verweij, J.⁴

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.